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Binding of serum and pre-immune serum to peptides of TAA (peptide array of patient no 9). Peptide array consisting of 17 TAA (MET, apolipoprotein L, 1, G1/S-specific cyclin-D1, telomerase, MUC1, survivin, Myc, p53, histone H1.2, NY-ESO-1, Her-2/neu, MMP11, WT-1, G2/mitotic-specific cyclin-B1, PRAME, MAGE A3, MAGE A1) was prepared. Their sequences were transformed into 15-mer peptides with a peptide-peptide overlap of 13 amino acids resulting in 4,399 different peptides, spotted in rows from top left to down right in duplicate to the array. (a) Staining with pre-immune serum (1:1000). (b) Staining with serum (after 8 vaccinations with MGN1601) (1:1000). Intensity of binding to peptides is visualized by intensity of red staining. 1.9% of all peptides (82 out of 4399) fulfill the described requirements for "immune response": Binding intensity in serum >1000, increase in binding in serum versus pre-immune serum >2, and at least one adjacent peptide with binding intensity in serum >500. with experimental variants of the murine vaccine. Tumor volumes at the end of the study of surviving mice and at the time of death of non-surviving mice were compared (One way ANOVA, followed by Tukey's multiple comparisons test). *** p < 0.001, * p < 0.05, n.s.: not significant, p > 0.05. 
Supplementary Materials and Methods
Cell culture. B25MOL cells were cultured in L15 -Leibovitz medium, supplemented with 10% (v/v) FBS, 1 mM glutamine, 1 mg/ml glucose, 0.1% (w/v) Na bicarbonate, 1 x MEM vitamins at 37°C in a 5% CO 2 atmosphere. Cell line B25MOL is restricted material and will not be shared. Renca (murine renal cell carcinoma cells, Cell Line Service, Eppelheim, Germany) were cultivated in EMEM medium, supplemented with 10% (v/v) FBS, at 37°C in a 5% CO 2 atmosphere. 
Manufacturing of MGN1601.
B25Mol cells were harvested by trypsinization. Transfection mixture was prepared by combining 4 different MIDGE vectors encoding human CD80, CD154, IL-7 and GM-CSF. Transient transfection was performed by electroporation using ECM630 electroporation system (BTX), with two cuvettes in parallel (400 V, 2400 µF, 100 ). Each cuvette contained 800 µl cell suspension (1.8 x 10 7 cells/ml) and 36 µg DNA. Thereafter, cells were incubated in low attachment culture dishes for 30 -90 min at 37°C for recovery. Cells were harvested, pooled, cooled to 4°C and gamma irradiated with 100 Gy (source: Cs
137
, four cycles, 25 Gy each) to assure that further multiplication of cells is impossible. Gene-modified and irradiated cells were immediately frozen in aliquots with a predefined freezing program and stored in the vaporous phase of liquid nitrogen. For final preparation of MGN1601 two aliquots of these cells were thawed and washed three times with PBS. An aliquot of the cell suspension was counted and percentage of viable cells was determined. These cells arenamed "vaccine cells", and supplemented with dSLIM. One dose of MGN1601 comprised 1.5 ml with 3.33 mg dSLIM/ml and 6.66 x 10 6 vaccine cells/ml (in total 1 x 10 7 vaccine cells + 5 mg dSLIM), and was applied to patients within 24 h after final preparation. Out of more than 100 doses the mean number of applied cells was 0.9 x 10 7 (+/-0.7 x 10 6 ) and mean percentage of viable cells was 94.5% (+/-1.5).
For the murine homologue of MGN1601, Renca cells were used instead of B25Mol cells, and MIDGE vectors encoding the murine variants of CD80, CD154, IL-7 and GM-CSF were gene-modified by electroporation. All other steps were performed as described for MGN1601. In vitro expression data of the murine homologue of the vaccine were comparable to those of MGN1601 (Figure 4a Cytokine analysis. Cell culture supernatant from cultivated vaccine cells was collected after the indicated cultivation duration (mainly 4 h) and kept frozen until analysis. Quantification of GM-CSF and IL-7 by was done by specific ELISA according to the instructions of the manufacturer (Human GM-CSF Immunoassay, #DGM00, R&D Systems, Minneapolis, MN, USA; IL-7 human ELISA kit, #ab100574, Abcam, Milton, Great-Britain). For quantification of cytokine concentration at the application sites of the murine homologue of MGN1601 in mice, biopsy homogenates were thawed and centrifuged at 10,000g at 4°C for 10 minutes. Supernatants were used at appropriate dilutions (1:10 for GM-CSF, 1:2 for IL-7) and run in duplicates. ELISA was performed according to instructions of the manufactures (Quantikine mouse IL-7 ELISA, #M7000, R&D Systems; mouse GM-CSF ELISA (#BMS612, eBioscience). Optical densities at 450 nm and 595 nm were measured with a Multimode plate reader (Mithras LB 940 Berthold Technologies).
RNA Microarray analysis. mRNA was extracted from cultivated cells either freshly harvested or after freezing (1 x 10 6 cells/sample) using RNAzol® RT according to instructions of the manufacturer. These RNA samples were used in Human GeneChip® 1.0 ST (Affymetrix Inc.) analysis. RNA processing and hybridization were performed according to the Affymetrix standard protocol. Data analysis was performed with open source statistical software R using oneChannelGUI package available within Bioconductor 1 . First, scanned images were inspected for quality control using principal component analysis and hierarchical cluster analysis. In order to obtain gene expression level the intensity values from scanned microarrays were preprocessed by using Robust Multi Array average (RMA 2 ). Differentially expressed genes were identified using the bayesian adjusted t-statistics from linear models for microarray data (limma) 3 . Genes that show more than threefold change were considered as differentially expressed (p < 0.05). Data are MIAME-compliant deposited with accession number GSE61634.
Peptide array analysis. Each array was used in a first round for analysis of pre-immune serum and, after stripping (PBS, pH 7.4 / 0.05% Tween 20 for 2 x 1 min), in a second round for analysis of the corresponding serum and in a third round for detection of control peptides. Arrays were blocked with Rockland blocking buffer MB-070 (60 min before the first assay). Sera were diluted 1:1000 with PBS, pH 7.4 with 0.05% Tween 20 and 10% Rockland blocking buffer and incubated for 16 h at 4°C shaking at 500 rpm with a peptide array. Detection of bound antibodies was performed with a 1:5000 dilution of F(ab´)2 goat anti-human IgG(H+L) conjugated toDyLight680 (KPL) for 30 min at RT. Control spots were analyzed with monoclonal anti-HA (12CA5)-LL-Atto680 and monoclonal anti-FLAG(M2)-LL-Atto800 antibodies. Visualization was done using a LI-COR Odyssey Imaging System with scanning offset 1 mm, resolution 21 µm, and scanning intensity "green/red" of 7/7. Quantification of spot intensities and peptide annotation were done with PepSlide® Analyzer. A software algorithm calculates the standard deviation of foreground median intensities. Mean deviations of repeat determinations (N = 4399) per patient were calculated and resulted in 12.0% (+/-2.4) for pre-immune sera and 14.0% (+/-3.9) for sera.
Treatment of NMRI mice for injection site biopsy (allogeneic setting)
. 48 mice were randomly assigned to one of two treatment groups. One single dose of the murine homologue of MGN1601 (1 x 10 7 (murine) vaccine cells supplemented with 5 mg dSLIM in 100 µl PBS) or PBS (control group) was distributed equally at two injection sites (left and right flank). Bubble seen after application was marked. After indicated time points (2, 4, 6, 8, 12, 26, 50 and 170 h) three mice of each group were sacrificed. Biopsies of each application site (2 biopsies per mouse) were taken. Tissue samples (ca. 50 µl) were homogenized in 200 µl PBS (supplemented with 1 mM EDTA, 5 µl proteinase inhibitor mix (Sigma, #P8340)), resulting in a dilution of about factor 5. Biopsy homogenates were then immediately flash frozen in liquid nitrogen. Samples were stored at -80°C until final analysis.
Treatment of NMRI mice for quantification of antibody titer and analysis of immune cells at the application site (allogeneic setting)
. 20 mice were randomly assigned to one of two treatment groups. 8 doses of the murine homologue of MGN1601(2 x 10 6 murine vaccine cells + 1 mg dSLIM each) or PBS (control group) were distributed equally to four injection sites (two left + two right flank) once weekly to NMRI mice. One week after the 8 th application blood was collected serum was prepared and analyzed for antibodies recognizing lysate of Renca cells. For this, Renca cells were subjected to two freeze-thaw cycles followed by gentle homogenization on ice with a potter tissue homogenizer after addition of proteinase inhibitor cocktail. After three centrifugations at 10,000g for 10 min each the lysate was stored at -20°C until use. ELISA plates were coated with Renca-lysate and blocked with BSA. After 1:50 pre-dilution in PBS, sera were serially diluted 1:3 in PBS seven times (final dilution 1:109350). Immobilized antibodies were detected by biotinylated antibody against mouse IgG, followed by incubation with streptavidin-peroxidase complex. Buffer was used instead of sera to measure the blank value and titer was calculated as multiples of 18-fold blank value.
One week after the 8 th application skin sections of the application sites were gained and used for immunohistochemical analysis. Frozen tissue sections were prepared and stained with HE. Presence of CD4 + , CD8 + and CD86 + positive cells were analyzed using the specific antibodies and peroxidase conjugated anti-rat antibodies. Quantification was performed visually with 4 scoring levels: 0 (no staining), 1 (slight staining), 2 (moderate staining), 3 (pronounced staining).
Treatment of NMRI mice for quantification of cytotoxicity of spleen cells and spleen weights (allogeneic setting)
. 46 NMRI mice were randomly assigned to one of four treatment groups (12 mice each for control group, high dose group and low dose group, 10 mice for recovery group). Mice were vaccinated either with low dose of the murine vaccine (2 x 10 6 murine vaccine cells supplemented with 1 mg dSLIM) or high dose (1 x 10 7 murine vaccine cells supplemented with 5 mg dSLIM) or PBS (control group) 13 times once weekly each. Each application was distributed equally to four injection sites (two into left and two into right flank). A recovery group that had been treated with the high doses or PBS was housed for additional 4 weeks after the 13 th application.
Cytotoxicity Assay: One week (5 weeks for recovery group) after the 13 th application of the murine vaccine mice were sacrificed, spleens was removed, separately minced and individual cell suspensions were successively passed through 200 μm and 50 μm filters. After lysis of erythrocytes spleen cells were washed twice with MEM and suspended in 1 ml MEM. 1 x 10 7 spleen cells were cocultured for 12 hours with Renca cells in MEM in the presence of 100 U/ml IL-2 (Gibco/Invitrogen, (PMC0023) specific activity: 2.5-10 x 10 6 U/mg). Thereafter, spleen cells were washed with DMEM (10% (v/v) FBS, 25 mM EDTA 50 μM 2-mercaptoethanol) and re-suspended at 5 x 10 6 spleen cells/ml. Cytotoxicity of spleen cells from PBS-treated mice was low for all animals and this value was subtracted from samples in order to correct for intraday variability of the assays. 
